Based on studies revealing that HDAC-inhibitors [10] with SFN in particular counteract everolimus resistance in renal cancer cell lines [11], it was postulated that SFN might be an innovative candidate to complement mTOR inhibition in bladder cancer therapy. This evidence concerns the gene HDAC9 and urinary bladder cancer.